National Cancer Institute Press Release: Low-dose Steroid Combined with Lenalidomide Prolongs Survival Compared with High-dose Steroid for Multiple Myeloma Treatment
Mayo Clinic Press Release: Multiple Myeloma Clinical Trial Closes Early Due to Superior Results of Comparative Treatment
Celgene Press Release: ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports LENALIDOMIDE Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
Abstract: Phase III trial of lenalidomide plus high-dose dexamethasone compared to lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma
Understanding Revlimid®
Understanding Thalidomide Therapy
Understanding Dexamethasone and Other Steroids
National Institute Of Health Release: Low-dose Steroid Combined with Lenalidomide Prolongs Survival Compared with High-dose Steroid for Multiple Myeloma Treatment
Mayo Clinic Cancer Center announced today that a multiple myeloma clinical trial has shown a significant improvement in survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone.
(E4A03): A trial coordinated by the Eastern Cooperative Oncology Group. S. V. Rajkumar, S. Jacobus, N. Callander, R. Fonseca, D. Vesole, M. Williams, R. Abonour, D. Siegel, P. Greipp
The clinical trial was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG).
back
print
related articles
Be the first to comment